|Bid||66.98 x 800|
|Ask||67.02 x 2200|
|Day's Range||66.45 - 67.47|
|52 Week Range||60.32 - 79.61|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||14.76|
|Earnings Date||Jul 23, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||2.52 (3.87%)|
|1y Target Est||80.51|
Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is Gilead stock a buy right now? Read on for a full analysis.
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.
While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.
Companies big and small have a variety of diabetes-related drugs in different stages of development.
A Texas biotech developing cell therapy treatments for multiple viruses will have offices in both Cambridge and Houston after nabbing an investment from newly launched ElevateBio.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc...
O’Day faced questioning at a Thursday hearing over the high price of Truvada, a medicine approved to treat HIV and prevent infection. Activists claim that the price prevents at-risk people from accessing the drug and has helped keep infection rates high. Truvada’s annual list price has nearly tripled in the U.S. to more than $20,000 over the past 15 years. News broke in April that the government is reviewing patents on Truvada’s preventative use that could entitle taxpayers to millions in royalties.
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
Gilead Sciences (GILD) is a major biopharmaceuticals producer focusing on life-threatening diseases. Founded in 1987 by Michael Riordan, a 29-year-old medical doctor, Gilead has grown to over $22 billion in revenues, notes George Putnam, editor of The Turnaround Letter.
The Gilead CFO is using her career and platform to enable the next generation to come up and succeed.
-- New Safety Data Involving Steroid Use and New Subpopulation Analyses from Pivotal ZUMA-1 Trial to Provide Greater Understanding of Yescarta® in Patients with Relapsed or Refract
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Pharmaceutical giant Gilead Sciences engaged in a "long-running scheme" to block generic competition of its combination drug "cocktails" to treat HIV. The complaint, filed in the U.S. District Court in San Francisco, names drugmakers Bristol-Myers Squibb and Johnson & Johnson subsidiary Janssen Pharmaceuticals as co-defendants. The plaintiffs in the suit claim that Gilead's actions caused the cost of the life-saving treatment to rise.
Buy Services, Sell Goods, Says Goldman Sachs If Tariff War Explodes The people at Goldman Sachs (NYSE:GS) may know a bit about trading, or maybe not, but either way, they’re saying to sell goods stocks and buy services stocks if the Chinese retaliate to the Trump Administration’s latest move to jack up tariffs on $200 […]The post Market Morning: Kudlow Cracks, Brexiters Rage, Gilead Butters Up FDA, Philip Morris Backtracks appeared first on Market Exclusive.